Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | BRAF | P15056 | 2/20 | 0.44 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.43 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | SMO | Q99835 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2740272 | 0.89 | MEN1 (0.48) | SIRT1MEN1KMT2AMAPTTP53 | |
| SCHEMBL2740273 | 0.85 | STK33 (0.54) | SIRT1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2740269 | 0.84 | MAPT (0.60) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL2624667 | 0.83 | MAPT (0.57) | SIRT1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2624496 | 0.80 | SIRT1 (0.60) | SIRT1NPC1RAB9AMAPTTP53 | |
| SCHEMBL2740266 | 0.80 | BRAF (0.47) | SIRT1MEN1KMT2AMAPTTP53 | |
| SCHEMBL2740256 | 0.80 | MAPT (0.59) | SIRT1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL2740268 | 0.78 | STK33 (0.59) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL2740257 | 0.78 | L3MBTL1 (0.61) | SIRT1MEN1KMT2AMAPTHPGD | |
| SCHEMBL2740280 | 0.78 | SIRT1 (0.47) | SIRT1NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9585907-B2 | Methods and compositions for modulating Tau levels | THE J. DAVID GLADSTONE INSTITUTES (US) | 2017-03-07 | — | — | US | disclosed |
| US-9585907-B2 | Methods and compositions for modulating Tau levels | THE J. DAVID GLADSTONE INSTITUTES (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160015733-A1 | METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS | THE J. DAVID GLADSTONE INSTITUTES | 2016-01-21 | — | — | US | disclosed |
| US-20160015733-A1 | METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS | THE J. DAVID GLADSTONE INSTITUTES | 2016-01-21 | — | — | US | disclosed |
| US-9040521-B2 | Methods and compositions for modulating tau levels | THE J. DAVID GLADSTONE INSTITUTES (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040521-B2 | Methods and compositions for modulating tau levels | THE J. DAVID GLADSTONE INSTITUTES (US) | 2015-05-26 | — | — | US | disclosed |
| US-8748464-B2 | Use of SIRT1 activators or inhibitors to modulate an immune response | THE J. DAVID GLADSTONE INSTITUTES (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748464-B2 | Use of SIRT1 activators or inhibitors to modulate an immune response | THE J. DAVID GLADSTONE INSTITUTES (US) | 2014-06-10 | — | — | US | disclosed |
| US-20140030295-A1 | Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response | THE J. DAVID GLADSTONE INSTITUTES (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140030295-A1 | Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response | THE J. DAVID GLADSTONE INSTITUTES (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2007019346-A1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019344-A1 | IMIDAZO [2,1-B] THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019417-A1 | OXAZOLOPYRIDINE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019416-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140030295-A1 | Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response | SIRT1, SIRT2, NFATC1 | SIRT1 1/4885NPC1 3045/4885RAB9A 2947/4885 |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRT2, SIRT1, SIRT3 | SIRT1 2/4885NPC1 3623/4885RAB9A 515/4885 |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRT1, SIRT3, SIRT2 | SIRT1 1/4885NPC1 2905/4885RAB9A 1526/4885 |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRT2, SIRT1, SIRT3 | SIRT1 2/4885NPC1 3657/4885RAB9A 589/4885 |
| US-20160015733-A1 | METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS | MAPT, NEFM, PSEN2 | SIRT1 528/4885NPC1 478/4885RAB9A 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.